N
IMRX icon

Nuveen’s Immuneering IMRX Stock Holding History

Nuveen’s Portfolio IMRX Stock Details IMRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-44,049
Closed -$127K – 3375
2024
Q1 		$127K Hold
44,049
– – ﹤0.01% 3234
2023
Q4 		$324K Buy
44,049
+3,504
+9% +$23.3K ﹤0.01% 3131
2023
Q3 		$311K Hold
40,545
– – ﹤0.01% 2955
2023
Q2 		$411K Buy
+40,545
New +$390K ﹤0.01% 2959
2022
Q2 		– Sell
-27,047
Closed -$196K – 3367
2022
Q1 		$196K Buy
27,047
+15,287
+130% +$147K ﹤0.01% 3197
2021
Q4 		$247K Hold
11,760
– – ﹤0.01% 3205
2021
Q3 		$312K Buy
+11,760
New +$316K ﹤0.01% 3245

Other funds holding IMRX

Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Nuveen's IMRX Position: Q2 2024 in Review

Nuveen sold out of Immuneering (IMRX) in Q2 2024, closing a stake of 44,049 shares — an estimated $127K sold.

Nuveen first reported a position in IMRX in Q3 2021 and held it in 7 quarters. The position peaked at $411K in Q2 2023. 59 funds tracked by Wall St. Rank hold IMRX as of Q2 2024.

  • Nuveen reported no remaining Immuneering position as of Q2 2024 after selling out during the quarter.
  • Nuveen sold 44,049 Immuneering shares in Q2 2024, an estimated $127K.
  • Nuveen first reported a position in Immuneering in Q3 2021 and held it in 7 quarters.
  • Nuveen's Immuneering position peaked at $411K in Q2 2023.
  • 59 funds tracked by Wall St. Rank held Immuneering as of Q2 2024.

Based on Nuveen's 13F filing for Q2 2024, filed 9 Aug 2024.